The BiliSeq molecular test developed at UPMC doubled detection sensitivity for bile duct cancer compared to standard pathology.
Key Details
- 1BiliSeq detected 82% of bile duct cancers vs. 44% with pathology alone in a six-year, multi-center study of over 2,000 patients.
- 2Combining BiliSeq with pathology increased detection up to 90% while minimizing false positives for benign disease.
- 3The test identifies actionable genetic mutations in about 20% of patients, informing care changes in nearly a third of those cases.
- 4BiliSeq maintains high performance in at-risk subgroups, detecting up to 86% of cancers in high-risk patients like those with PSC.
- 5Results have direct implications for diagnosis clarification and treatment—including transplant decisions—where imaging and standard biopsies often fail.
Why It Matters
This study demonstrates transformative potential for molecular diagnostics to support radiology and pathology in challenging cancer cases, reducing uncertainty for clinicians and patients. Enhanced diagnostic accuracy may lead to faster, more tailored interventions, especially in hard-to-assess biliary cancers.
Source
EurekAlert
Related News
•EurekAlert
AI-Powered OCT Enables Rapid 'Optical Biopsy' for Early Endometrial Cancer Detection
A team at Washington University has developed a catheter-based 3D OCT system with AI to quickly and noninvasively detect early endometrial cancers.
•EurekAlert
AI Clinical Reasoning in Diagnostics and Digital Fatigue in Healthcare
Recent JMIR features explore large language models in clinical diagnostics and digital fatigue among healthcare professionals.
•EurekAlert
KAIST, MIT, Microsoft Develop Efficient AI Image Upsampling for Robotics
KAIST, MIT, and Microsoft have created 'Upsample Anything,' a training-free AI method to restore high-resolution visual data from compressed images with up to 16x improved GPU memory efficiency.